Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1), its ligand (PD-L1), or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) are among the mostly used therapeutics in various cancers in clinical trials and practice [1,2]. The gene discussed is CTLA4; the disease is cancer.